JP2010526153A5 - - Google Patents

Download PDF

Info

Publication number
JP2010526153A5
JP2010526153A5 JP2010507601A JP2010507601A JP2010526153A5 JP 2010526153 A5 JP2010526153 A5 JP 2010526153A5 JP 2010507601 A JP2010507601 A JP 2010507601A JP 2010507601 A JP2010507601 A JP 2010507601A JP 2010526153 A5 JP2010526153 A5 JP 2010526153A5
Authority
JP
Japan
Prior art keywords
antisense nucleic
antibody
seq
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010507601A
Other languages
English (en)
Japanese (ja)
Other versions
JP5924863B2 (ja
JP2010526153A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/062789 external-priority patent/WO2008137901A2/en
Publication of JP2010526153A publication Critical patent/JP2010526153A/ja
Publication of JP2010526153A5 publication Critical patent/JP2010526153A5/ja
Application granted granted Critical
Publication of JP5924863B2 publication Critical patent/JP5924863B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010507601A 2007-05-06 2008-05-06 Gi症候群及び移植片対宿主病を治療及び予防する方法 Active JP5924863B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91629807P 2007-05-06 2007-05-06
US60/916,298 2007-05-06
PCT/US2008/062789 WO2008137901A2 (en) 2007-05-06 2008-05-06 Methods for treating and preventing gi syndrome and graft versus host disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015256345A Division JP6251234B2 (ja) 2007-05-06 2015-12-28 Gi症候群及び移植片対宿主病を治療及び予防する方法

Publications (3)

Publication Number Publication Date
JP2010526153A JP2010526153A (ja) 2010-07-29
JP2010526153A5 true JP2010526153A5 (enExample) 2011-06-23
JP5924863B2 JP5924863B2 (ja) 2016-05-25

Family

ID=39944232

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010507601A Active JP5924863B2 (ja) 2007-05-06 2008-05-06 Gi症候群及び移植片対宿主病を治療及び予防する方法
JP2015256345A Active JP6251234B2 (ja) 2007-05-06 2015-12-28 Gi症候群及び移植片対宿主病を治療及び予防する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015256345A Active JP6251234B2 (ja) 2007-05-06 2015-12-28 Gi症候群及び移植片対宿主病を治療及び予防する方法

Country Status (6)

Country Link
US (6) US8562993B2 (enExample)
EP (1) EP2152287B1 (enExample)
JP (2) JP5924863B2 (enExample)
AU (1) AU2008247368B2 (enExample)
CA (1) CA2686722C (enExample)
WO (1) WO2008137901A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008137901A2 (en) 2007-05-06 2008-11-13 Sloan Kettering Institute For Cancer Research Methods for treating and preventing gi syndrome and graft versus host disease
JP5769417B2 (ja) 2007-08-16 2015-08-26 ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング/マギル ユニバーシティ 腫瘍細胞由来微小胞
US20100255514A1 (en) * 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
US20130203081A1 (en) * 2010-04-13 2013-08-08 Janusz Rak Tumor cell-derived microvesicles
CA3172599C (en) * 2012-05-25 2025-10-07 Sloan Kettering Institute For Cancer Research ANTI-CERAMID ANTIBODY AND RELATED ANTIGEN BINDING FRAGMENT
EP3177650B1 (en) * 2014-08-07 2025-11-05 Memorial Sloan-Kettering Cancer Center Anti-ceramide antibodies
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CN107530376A (zh) * 2015-02-18 2018-01-02 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
JP6803339B2 (ja) 2015-04-21 2020-12-23 エンリヴェックス セラピューティクス リミテッド 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
WO2017119988A2 (en) * 2015-12-10 2017-07-13 Memorial Sloan Kettering Cancer Center Radioprotection by wnt activation
CN109069539A (zh) 2016-02-18 2018-12-21 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
EP3612211A4 (en) * 2017-04-17 2021-02-17 Memorial Sloan-Kettering Cancer Center INTESTINAL PROTECTIVE EFFECT OF RIG-I / MAVS AND STING ACTIVATION
WO2020231629A1 (en) * 2019-05-16 2020-11-19 Snake River Bioscience, Inc. Compositions and methods for the treatment of major depressive disorder
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
CN112255221A (zh) * 2020-10-16 2021-01-22 航科中投生物技术(北京)有限公司 一种生物防护过滤介质浓度及喷涂效果的比色鉴定方法
US20240158487A1 (en) * 2021-03-16 2024-05-16 Memorial Sloan-Kettering Cancer Center Wound healing enhancement with anti-ceramide antibodies
AU2022241760A1 (en) * 2021-03-23 2023-10-05 Spinogenix, Inc. Certain fascin binding compounds for spinogenesis
WO2025076313A1 (en) * 2023-10-04 2025-04-10 Memorial Sloan-Kettering Cancer Center Combination administration of bone marrow and anti-ceramide antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
JPH02128697A (ja) * 1988-11-09 1990-05-17 Hoechst Japan Ltd 抗フコシルセラミドモノクローナル抗体
US5643602A (en) 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
US5851548A (en) 1995-06-07 1998-12-22 Gen-Probe Incorporated Liposomes containing cationic lipids and vitamin D
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
WO1997037637A1 (en) 1996-04-04 1997-10-16 Ortho Pharmaceutical Corporation Liposome-based topical vitamin d formulation
WO1998019167A2 (en) * 1996-10-29 1998-05-07 Fred Hutchinson Cancer Research Center, Inc. Cell stress regulated human mhc class i gene
AU2002211681A1 (en) * 2000-10-12 2002-04-22 Curagen Corporation Proteins and nucleic acids encoding same
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
DE10239531A1 (de) * 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
CA2531878A1 (en) 2003-05-09 2005-03-24 Curagen Corporation Therapeutic use of g53135-05(fgf-20) in radiation protection
KR100565437B1 (ko) 2003-07-31 2006-03-30 중앙대학교 산학협력단 신규한 스핑고마이엘리나제 효소, 그에 대한 항체, 안티센스 및 제조방법
JP2008546647A (ja) 2005-06-08 2008-12-25 デューク ユニバーシティ 移植のための抗−cd19抗体治療
CA2642020C (en) 2006-02-14 2014-10-07 Cellerant Therapeutics, Inc. Methods and compositions for enhancing engraftment of hematopoietic stem cells
WO2008137901A2 (en) 2007-05-06 2008-11-13 Sloan Kettering Institute For Cancer Research Methods for treating and preventing gi syndrome and graft versus host disease

Similar Documents

Publication Publication Date Title
JP2010526153A5 (enExample)
Vacas et al. High-mobility group box 1 protein initiates postoperative cognitive decline by engaging bone marrow-derived macrophages
KR100883078B1 (ko) 항-tnf 항체, 조성물, 방법 및 용도
CN102596992B (zh) 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
DK2513146T3 (en) Antibodies against ROR1 capable of inducing cell death by CLL
KR20060054174A (ko) 항-아밀로이드 항체, 조성물, 방법 및 용도
JP2005512522A (ja) Il−13ムテインタンパク質、抗体、組成物、方法および使用
KR20100075639A (ko) 인간 항-아밀로이드 항체, 조성물, 방법 및 용도
KR20120089346A (ko) 높은 차단 활성을 갖는 항-C5a 결합 부분
JP2012518420A5 (enExample)
JP2010533171A5 (enExample)
JP2010516290A5 (enExample)
CN101415439A (zh) Glp-1激动剂、组合物、方法和用途
JP2019088329A5 (enExample)
JP2013107899A5 (enExample)
JP2007525946A (ja) Cngh0010特異的ポリヌクレオチド、ポリペプチド、抗体、組成物、方法および使用
JP2015524413A5 (enExample)
JP2010500370A5 (enExample)
JP2010533705A5 (enExample)
JP2017529326A5 (enExample)
RU2015120365A (ru) Ингибирующие олигонуклеотиды и их применение
Wang et al. Tetrahedral framework nuclear acids can regulate interleukin-17 pathway to alleviate inflammation and inhibit heterotopic ossification in ankylosing spondylitis
WO2019029129A1 (zh) 一种针对IL-17和TNF-α的双特异性融合蛋白
JP7066669B2 (ja) 炎症性関節疾患の治療方法
JP2005504522A5 (enExample)